Alexandre Jagerschmidt
Sanofi (France)(FR)
Publications by Year
Research Areas
Asthma and respiratory diseases, Sinusitis and nasal conditions, Allergic Rhinitis and Sensitization, Neuropeptides and Animal Physiology, Dermatology and Skin Diseases
Most-Cited Works
- → Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma(2019)198 cited
- → Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis(2017)106 cited
- → Idiopathic Pulmonary Fibrosis(2018)103 cited
- → Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis(2020)79 cited
- → Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis(2019)73 cited
- → Mutation of Asp100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction.(1995)37 cited
- → Double-blind, Randomized, 8-week Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis(2018)36 cited
- → His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity(1996)34 cited
- → Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse(2020)33 cited
- → Identification and Characterization of Various Cholecystokinin B Receptor mRNA Forms in Rat Brain Tissue and Partial Determination of the Cholecystokinin B Receptor Gene Structure(1994)26 cited